Lung Cancer
Conditions
Keywords
squamous cell lung cancer, large cell lung cancer, stage IIIA non-small cell lung cancer, adenosquamous cell lung cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known if chemotherapy plus radiation therapy is more effective than chemotherapy alone before surgery in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying docetaxel and cisplatin with or without radiation therapy to see how well they work when given before surgery in treating patients with stage IIIA non-small cell lung cancer that has spread to lymph nodes in the chest.
Detailed description
The main objective of this trial is to compare feasibility and efficacy of sequential neoadjuvant chemoradiotherapy with 44 Gy concomitant boost to neoadjuvant chemotherapy alone. Secondary objectives are to assess the value of PET in predicting pathological response and eventfree survival in stage IIIA NSCLC, and a health economic analysis of the two regimens. Further to compare the amount of serum DNA in patients with stage IIIA, pN2 NSCLC before chemotherapy, before surgery and at the second follow-up visit (i.e. four months after surgery or treatment failure for patients who can not be operated) in patients randomized into the trial SAKK 16/00 and to correlate the DNA variation with tumor response, remission duration and overall survival. OUTLINE: This is a prospective randomized phase III trial. Patients are stratified according to mediastinal bulk (5 cm or more vs less than 5 cm), weight loss in the past 6 months (5% or more vs less than 5%), and participating center. Patients are randomized to 1 of 2 treatment arms.
Interventions
DRUGChemotherapy
Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
RADIATIONRadiotherapy
Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
PROCEDURESurgery
3-4 weeks after termination of radiotherapy
Sponsors
Swiss Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer * Squamous, adenosquamous, large cell, or poorly differentiated * Stage IIIA (T1-3, N2, M0) * N2 disease confirmed by 1 of the following: * Mediastinoscopy * Bronchoscopy with fine-needle aspiration or esophagoscopy * All N3 lymph nodes must be negative by positron-emission tomography (PET) AND CT scan (\< 1 cm in the largest diameter) * PET scan * Both the primary tumor and at least 1 N2 lymph node must be positive in PET scan * At least 1 of the PET scan positive N2 lymph nodes is positive in the CT scan (\> 1 cm in the largest diameter) * All N3 lymph nodes negative in PET scan PATIENT CHARACTERISTICS: Age: * 18 to 75 Performance status: * WHO 0-1 Life expectancy: * Not specified Hematopoietic: * WBC at least 4,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin normal * AST/ALT no greater than 1.5 times upper limit of normal (ULN) * Alkaline phosphatase no greater than 2.5 times ULN Renal: * Creatinine clearance greater than 60 mL/min Cardiovascular: * Cardiac function normal * No unstable cardiac disease requiring treatment * No congestive heart failure * No angina pectoris even if medically controlled * No significant arrhythmia * No myocardial infarction in the past 3 months Pulmonary: * Lung function appropriate Neurologic: * No history of significant neurologic or psychiatric disorders * No psychotic disorders * No dementia * No seizures Other: * No other prior or concurrent malignancies except nonmelanoma skin cancer, adequately treated carcinoma in situ of the cervix, or any other neoplastic disease with a disease-free interval ≥ 5 years * No active uncontrolled infection * No uncontrolled diabetes mellitus * No gastric ulcers * No pre-existing peripheral neuropathy greater than grade 1 * No contraindications to corticosteroids * No other serious underlying medical condition that would preclude study participation * No socioeconomic or geographic condition that would preclude study participation * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior cytostatic chemotherapy Endocrine therapy: * No concurrent prednisone except for treatment of acute hypersensitivity reactions or chronic low-dose treatment initiated more than 6 months prior to study entry (i.e., no greater than 20 mg methylprednisolone or equivalent) Radiotherapy: * No prior radiotherapy to chest Surgery: * Not specified Other: * At least 30 days since participation in another clinical study * No other concurrent experimental drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | 1 month after surgery | Time from randomization to relapse/progression/second tumor/death, whichever occurs first (for all randomized patients). If no event is observed, the patients will be censored at the last time they were known to be alive. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity (hematological, renal and neurological toxicities, nausea and vomiting, weight changes as well as esophageal toxicities) | During treatment | Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading. Special attention shall be given to hematological, renal and neurological toxicities, nausea and vomiting, weight changes as well as esophageal toxicities. |
| Complete resection rate after surgery | 1 month after surgery | Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading. |
| Objective response rate measured after completion of chemoradiotherapy | 43 days | Response rate will be evaluated according to the 1. WHO response criteria 2. TNM classification after surgery. |
| Postoperative mortality assessed | 1 month after surgery | All deaths occurring within 30 days of the thoracic surgery to remove the primary tumor |
| Overall survival | Life-long follow-up until death of patient (up to 30 years) | Calculated from randomization to the date of death from any cause. Patients not experiencing an event will be censored at the last time they were known to be alive. |
| Failure pattern | Life-long follow-up until death of patient (up to 30 years) | Defined as location of first tumor progression or relapse. Failure can be local relapse (area of primary tumor or mediastinum), distant relapse (all others) or the combination thereof. |
| Operability | 1 month after chemo | Patients who are able to undergo radical resection of their lung cancer after neoadjuvant therapy, as assessed by the thoracic surgeon. |
Countries
Germany, Serbia, Switzerland
Outcome results
None listed